LEADER 04546nam  2201417z- 450 
001 9910580203103321
005 20231214133238.0
035   $a(CKB)5690000000012059
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87430
035   $a(EXLCZ)995690000000012059
100   $a20202207d2022      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aTherapeutic Potential of Plant Secondary Metabolites in the Treatment of Diseases and Drug Development
210   $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022
215   $a1 electronic resource (334 p.)
311   $a3-0365-3881-X 
311   $a3-0365-3882-8 
330   $aThe importance of natural products, and especially plant secondary metabolites, for the treatment of diseases and drug development has already been obvious in medicine for several thousand years. Thus, this Special Issue of MDPI Biomedicines collects eight top articles from the field as regular full papers in addition to five reviews. All of the published papers are a vibrant source of information on the therapeutic potential of plant secondary metabolites in the treatment of diseases and drug development.
606   $aTechnology: general issues$2bicssc
606   $aChemical engineering$2bicssc
610   $aCannabis sativa (Cannabis)
610   $acannabinoids
610   $atetrahydrocannabinol (THC)
610   $acannabidiol (CBD)
610   $acannabinoid receptors (CB1 and CB2)
610   $aPapaver somniferum (opium poppy)
610   $asecondary metabolites
610   $aursolic acid
610   $aNSCLC
610   $atumorsphere
610   $aEGFR
610   $aSTAT3
610   $aMMP2
610   $aPD-L1
610   $aMAFLD
610   $atanshinone IIA
610   $aphytochemical
610   $alipogenesis
610   $alipid accumulation
610   $aLXR?
610   $amalaria
610   $aquinine
610   $achloroquine
610   $aartemisinin
610   $aonchocerciasis
610   $aivermectin
610   $amoxidectin
610   $acancer
610   $avincristine
610   $avinblastine
610   $aanabolic
610   $adiabetes
610   $aDuchenne muscular dystrophy
610   $a?-ecdysone
610   $aecdysteroid
610   $aecdysterone
610   $aMas1
610   $aosteoporosis
610   $asarcopenia
610   $aCOVID-19
610   $acardiometabolic diseases
610   $arespiratory diseases
610   $anatural product
610   $aSARS-CoV-2
610   $alung cancer
610   $aUnited States Food and Drug Administration-approved drug
610   $anatural remedy
610   $atriterpenoid
610   $amolecular ribbon
610   $aHuisgen 1,3-dipolar cycloaddition
610   $aamide bond
610   $amultifunctional PEG3 derivative
610   $aantimicrobial activity
610   $aanti-HIV activity
610   $acytotoxicity
610   $asupramolecular self-assembly
610   $aphytocannabinoids
610   $acannabichromene
610   $athermos-TRPs
610   $aTRPA1
610   $a?,?-dimethylheptyl effect
610   $abetulinic acid
610   $aBODIPY
610   $abevirimat
610   $acell-cycle
610   $afluorescent microscopy
610   $amaturation inhibitor
610   $acapsaicinoids
610   $aendocannabinoidome
610   $amicrobiota
610   $aoverweight
610   $aobesity
610   $afood intake
610   $alipidomics
610   $ametabolism
610   $aalkaloids
610   $amembrane fusion
610   $aviral fusion inhibitor
610   $aantiviral therapy
610   $acurcumin
610   $acancer cells
610   $abioavailability
610   $acurcumin derivatives
610   $acurcumin analogues
610   $acurcumin delivery systems
610   $anatural product synthesis
610   $alignans
610   $ainflammation
610   $aNF-?B inhibition
615  7$aTechnology: general issues
615  7$aChemical engineering
700   $aDras?ar$b Pavel B$4edt$01303416
702   $aDras?ar$b Pavel B$4oth
906   $aBOOK
912   $a9910580203103321
996   $aTherapeutic Potential of Plant Secondary Metabolites in the Treatment of Diseases and Drug Development$93027019
997   $aUNINA